Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab + zimberelimab + chemotherapy versus nivolumab + chemotherapy in untreated advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma
2023-507522-16-00Phase 3Completed
- Sponsor
- Arcus Biosciences
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of domvanalimab and zimberelimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Arcus Biosciences. Primary endpoint: Overall survival. Started May 2023; status: completed.
02
Drugs
domvanalimabzimberelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-507522-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507522-16-00.